@article{ddba10adb1a94391bd0f8a216fcd74c4,
title = "A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder",
abstract = "Stimulant use disorders are both common and associated with suicidal ideation and attempts. The psychometric properties of the 12-item Concise Health Risk Tracking Scale Self-Report (CHRT-SR), a measure that was created to assess suicidal thinking and several factors associated with a propensity to act, has been established in persons with mood disorders. This is a secondary analysis to assess the CHRT-SR in 302 stimulant abusing patients that had participated in a clinical trial. A confirmatory factor analysis (CFA) was conducted to assess the factor validity of the 12-item CHRT-SR model with a second-order Propensity factor. The CHRT-SR total score and 2 factor scores (Propensity and Suicidal Thoughts) demonstrated acceptable internal consistency and test-retest reliabilities. These two subscales and the total score were modestly but significantly associated with measures of depression and life satisfaction, demonstrating construct validity. Two additional items assessing Impulsivity were also analyzed, and demonstrated acceptable internal consistency, test-retest reliability, and construct validity. The CHRT-SR appears to be a reliable and valid tool to assess suicidality in persons with stimulant use disorder.",
keywords = "CHRT-SR, Stimulant use disorder, Suicidality, Suicide risk",
author = "Katherine Sanchez and Killian, {Michael O.} and Mayes, {Taryn L.} and Greer, {Tracy L.} and Trombello, {Joseph M.} and Robert Lindblad and Grannemann, {Bruce D.} and Carmody, {Thomas J.} and Rush, {A. John} and Robrina Walker and Trivedi, {Madhukar H.}",
note = "Funding Information: Dr. Rush has received consulting fees from Akili, Brain Resource Inc., Compass Inc., Curbstone Consultant LLC, Eli Lilly, Emmes Corp, Liva-Nova, Mind Linc., Sunovion, Takeda USA, Taj Medical; speaking fees from Liva-Nova and Sing-Health; and royalties from Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX. (for the Inventory of Depressive Symptoms and its derivatives). He is also named co-inventor on two patents: U.S. Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS and U.S. Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. Dr. Trivedi has received consulting fees from or has served on the advisory boards of Alkeremes Inc., Akili Interactive, Allergan Pharmaceuticals, Arcadia Pharmaceuticals, Avanir Pharmaceuticals, Brintellix Global, Bristol Myers Squibb, Caudex, Cerecor, Forest Pharmaceuticals, Global Medical Education Inc, Health Research Associates, Insys, Johnson & Johnson Pharmaceutical Research & Development, Lilly Research Laboratories, Lundbeck Research USA, Medscape, Merck & Co. Inc, Mitsubishi Pharma, MSI Methylation Sciences – Pamlab Inc., Navitor, Otsuka America Pharmaceutical Inc., One Carbon Therapeutics, Otsuka America Pharmaceutical Inc., Pfizer Inc, and Takeda Global Research; royalties from Janssen Research and Development LLC; honoraria from the American Psychiatric Association; grants from the Agency for Healthcare Research and Quality (AHRQ) , Cancer Prevention and Research Institute of Texas (CPRIT) ( PP160121 ), National Institute of Mental Health (NIMH) ( U01 MH092221 , R25 MH101078 ), National Institute of Drug Abuse (NIDA) ( U10 DA020024 ), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ( R01 DK085512 ), National Center for Advancing Translational Sciences (NCATS) ( UL1 TR001105 ), Johnson & Johnson , PCORI ; and holds author agreements with Janssen Asia Pacific and Oxford University Press. Drs. Trombello currently owns stock in Merck and Gilead Sciences and within the past 36 months previously owned stock in Johnson & Johnson. Dr. Walker's research is funded by National Institute ofDrug Abuse (NIDA) ( U10 DA020024 ), and Alkermes, Inc. donated medication for a NIDA -funded study ( NCT03078075 ) unrelated to the current manuscript . Dr. Greer is a paid consultant for H Lundbeck A/S. Drs. Killian, Lindblad, and Carmody, Mrs. Mayes , and Mr. Grannemann have no conflicts to report. Funding Information: Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number U10DA020024 and UG1DA020024 (PI: Trivedi). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2018",
year = "2018",
month = jul,
doi = "10.1016/j.jpsychires.2018.03.012",
language = "English (US)",
volume = "102",
pages = "65--71",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",
}